ARTL News

(NASDAQ:ARTL) SOLANA BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the pricing of its previously announced underwritten public offering of 640,924 shares of its common stock at a price to the public of $4.40 per share and pre-funded warrants to purchase up to 40,894 shares of Artelo’s common stock at a price to the public of $4.399 per pre-funded warrant, which represents the per share public offering price of each share of Artelo’s common stock less the $0.001 per share exercise price for each pre-funded warrant. The aggregate gross proceeds from the offering are expected to be approximately $3.0 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purch

(NASDAQ:ARTL) SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced it has commenced an underwritten public offering of its common stock and/or pre-funded warrants. All shares of common stock and/or pre-funded warrants in the offering are to be offered by the Company. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

(NASDAQ:ARTL) SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, affirms that, based on the strength of the positive interim results from its Phase 2 CAReS trial of ART27.13 for cancer anorexia-cachexia syndrome (CACS) and the strong interest expressed by multiple pharmaceutical companies awaiting these results, it is well positioned to secure a development partner for ART27.13. CACS, a leading cause of death in cancer patients and affecting up to 80% of those living with cancer, currently has no FDA-approved treatment.

(NASDAQ:ARTL) Catalyst for Advancing Discussions with Pharmaceutical Companies that have Expressed Interest in ART27.13 for CACS

Safety and Pharmacokinetic Data Support Dosing of ART26.12 in Fed or Fasted Conditions

LA JOLLA, Calif.--(BUSINESS WIRE)-- #ANRE--Arialys' Nature Communications Paper Supports ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDAR Autoimmune Neuropsychiatric Disease

Artelo Biosciences advances ART26.12 for psoriasis and CIPN, while ART27.13 shows early promise in cancer-related anorexia studies.

Artelo Biosciences advances its pipeline with ART26.12 for neuropathic pain and ART27.13 for cancer-related anorexia, targeting 2025 milestones.